We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Doximity (DOCS - Free Report) closed at $41.42 in the latest trading session, marking a -1.76% move from the prior day. This change lagged the S&P 500's daily loss of 0.92%. At the same time, the Dow lost 0.96%, and the tech-heavy Nasdaq lost 1.6%.
The medical social networking site's shares have seen an increase of 1.91% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.68%.
The upcoming earnings release of Doximity will be of great interest to investors. The company's earnings report is expected on November 7, 2024. It is anticipated that the company will report an EPS of $0.26, marking a 18.18% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $127.05 million, indicating a 11.83% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $1.05 per share and a revenue of $520.23 million, demonstrating changes of +10.53% and +9.43%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Doximity is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Doximity is currently exchanging hands at a Forward P/E ratio of 39.98. This represents a premium compared to its industry's average Forward P/E of 19.41.
We can also see that DOCS currently has a PEG ratio of 3.83. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services industry had an average PEG ratio of 1.85 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 173, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Doximity (DOCS - Free Report) closed at $41.42 in the latest trading session, marking a -1.76% move from the prior day. This change lagged the S&P 500's daily loss of 0.92%. At the same time, the Dow lost 0.96%, and the tech-heavy Nasdaq lost 1.6%.
The medical social networking site's shares have seen an increase of 1.91% over the last month, surpassing the Medical sector's loss of 4.16% and falling behind the S&P 500's gain of 2.68%.
The upcoming earnings release of Doximity will be of great interest to investors. The company's earnings report is expected on November 7, 2024. It is anticipated that the company will report an EPS of $0.26, marking a 18.18% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $127.05 million, indicating a 11.83% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $1.05 per share and a revenue of $520.23 million, demonstrating changes of +10.53% and +9.43%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Doximity is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Doximity is currently exchanging hands at a Forward P/E ratio of 39.98. This represents a premium compared to its industry's average Forward P/E of 19.41.
We can also see that DOCS currently has a PEG ratio of 3.83. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services industry had an average PEG ratio of 1.85 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 173, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.